Prader-Willi syndrome or PWS is a rare condition that can affect children from 0 to 6 years of age. It is a multisystem genetic disorder caused by the loss of paternally expressed genes on chromosome ...

Aardvark Therapeutics is down 54% since Friday after the biotech said it detected “reversible cardiac observations” in a healthy volunteer study of its drug to treat extreme hunger in patients with ...

Soleno Therapeutics Inc. concealed issues with its first commercial drug, leading to stock declines after a short seller ...

The detection of certain cardiac issues in a study of healthy volunteers led Aardvark to pause a Phase 3 trial only months before an expected data readout.

Aardvark Therapeutics Inc. AARD shares are down during Monday’s premarket session following the company’s announcement to voluntarily pause its Phase 3 HERO trial for Prader-Willi Syndrome. The ...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the addition of a new Phase 3 development candidate to its rare disease portfolio, ACP-101 (intranasal carbetocin ...

WE’LL TALK TO YOU LATER. WELL, IMAGINE EATING ENOUGH MAYBE TOO MUCH, BUT NEVER FEELING FULL. THAT’S WHAT A NORTHLAND TODDLER LIVES WITH EVERY DAY. AND THIS WORLD WHERE DISEASE DAY CAME DECISIONS DONNA ...

A Prescription Drug User Fee Act target date of December 27, 2024 has been assigned to the application. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application ...

Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for ...

BOONE COUNTY, Ky. (WKRC) - It was a dream come true for a senior at Ryle High School who loves sports. Jacob Arnold is usually the team manager for the Raiders basketball team, but he got the nod to ...

-- Company recently completed a meeting with the FDA and plans to initiate a Phase 3 study in the fourth quarter of 2023 “Acadia’s acquisition of ACP-101 demonstrates our commitment to acquiring and ...